Identification of the HLA-DM/HLA-DR interface

被引:6
|
作者
Davies, Matthew N. [3 ]
Lamikanra, Abigail [4 ]
Sansom, Clare E. [1 ]
Flower, Darren R. [3 ]
Moss, David S. [1 ]
Travers, Paul J. [2 ]
机构
[1] Univ London Birkbeck Coll, Sch Crystallog, London WC1E 7HX, England
[2] Anthony Nolan Res Inst, Units 2 3, London NW3 2NU, England
[3] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Edward Jenner Inst, Oxford OX3 9DU, England
[4] Univ Oxford, John Radcliffe Hosp, Natl Blood Serv, Oxford OX3 9DU, England
基金
英国医学研究理事会;
关键词
MHC class II; HLA-DR; HLA-DM; homology modelling; energy minimisation; HISTOCOMPATIBILITY LEUKOCYTE ANTIGEN; INVARIANT CHAIN PEPTIDES; II MHC MOLECULES; BINDING GROOVE; DM; DISSOCIATION; EXCHANGE; HLA-DR3; POLYMORPHISM; COMPLEXES;
D O I
10.1016/j.molimm.2007.07.033
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human leukocyte antigen (HLA)-DM is a critical participant in antigen presentation that catalyzes the dissociation of the Class II-associated Invariant chain-derived Peptide (CLIP) from the major histocompatibility complex (MHC) Class II molecules. There is competition amongst peptides for access to an MHC Class II groove and it has been hypothesised that DM functions as a 'peptide editor' that catalyzes the replacement of one peptide for another within the groove. It is established that the DM catalyst interacts directly with the MHC Class II but the precise location of the interface is unknown. Here, we combine previously described mutational data with molecular docking and energy minimisation simulations to identify a putative interaction site of > 4000 angstrom(2) which agrees with known point mutational data for both the DR and DM molecule. The docked structure is validated by comparison with experimental data and previously determined properties of protein-protein interfaces. A possible dissociation mechanism is suggested by the presence of an acidic cluster near the N terminus of the bound peptide. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1063 / 1070
页数:8
相关论文
共 50 条
  • [41] Analysis of HLA-DM polymorphisms in sarcoidosis
    Ishihara, M
    Naruse, T
    Ohno, S
    Kawata, H
    Mizuki, N
    Yamagata, N
    Ishida, T
    Nose, Y
    Inoko, H
    HUMAN IMMUNOLOGY, 1996, 49 (02) : 144 - 146
  • [42] The mechanistic basis of HLA-DM function
    Zarutskie, JA
    Busch, R
    Mellins, ED
    Stern, LJ
    FASEB JOURNAL, 2001, 15 (04): : A675 - A675
  • [43] Low HLA-DM expression in RA
    Robert Busch
    Arthritis Research & Therapy, 3 (1)
  • [44] HLA-DR BOUILLABAISSE
    TROWSDALE, J
    LEE, J
    MCMICHAEL, A
    IMMUNOLOGY TODAY, 1983, 4 (02): : 31 - +
  • [45] Targeting HLA-DR
    Tay, Kevin
    Dunleavy, Kieron
    Wilson, Wyndham H.
    LEUKEMIA & LYMPHOMA, 2009, 50 (12) : 1911 - 1913
  • [46] HLA-DR IS A PROCOAGULANT
    CHELLADURAI, M
    HONN, KV
    WALZ, DA
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 178 (02) : 467 - 473
  • [47] The DMα and DMβ chain cooperate in the oxidation and folding of HLA-DM
    van Lith, Marcel
    Benham, Adam M.
    JOURNAL OF IMMUNOLOGY, 2006, 177 (08): : 5430 - 5439
  • [48] Stabilization of soluble, low-affinity HLA-DM/HLA-DR1 complexes by leucine zippers
    Busch, R
    Paschine, A
    Garcia, KC
    Mellins, ED
    JOURNAL OF IMMUNOLOGICAL METHODS, 2002, 263 (1-2) : 111 - 121
  • [49] Conformational alterations during biosynthesis of HLA-DR3 molecules controlled by invariant chain and HLA-DM
    Verreck, FAW
    Fargeas, CA
    Hämmerling, GJ
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2001, 31 (04) : 1029 - 1036
  • [50] The extent of HLA-DR expression on HLA-DR plus Tregs allows the identification of patients with clinically relevant borderline rejection
    Schaier, Matthias
    Seissler, Nicole
    Becker, Luis Eduardo
    Schaefer, Sebastian Markus
    Schmitt, Edgar
    Meuer, Stefan
    Hug, Friederike
    Sommerer, Claudia
    Waldherr, Ruediger
    Zeier, Martin
    Steinborn, Andrea
    TRANSPLANT INTERNATIONAL, 2013, 26 (03) : 290 - 299